Santoro joins SynteractHCR to further augment the organization’s drug and device development expertise. Most recently he served as chief medical officer for Novella Clinical. Prior to that he was vice president, Clinical Development and Medical Affairs for Protherics, a United Kingdom-based biopharmaceutical company specializing in oncology and critical care products. Before Protherics, Santoro spent 17 years in the CRO industry where he developed medical and clinical research capabilities to service clinical development programs.
Drawing on both CRO and pharmaceutical industry experience, Santoro is tasked with setting strategic direction for all medical affairs services at SynteractHCR. This includes building infrastructure and framework to further expand the CRO’s medical and scientific capabilities, as well as overseeing staff involved in supporting client projects.
“As the complexity of clinical trials increases, the role of medical affairs to effectively communicate with various stakeholders across the drug development spectrum continues to grow in importance. With his deep medical and operational knowledge and experience in both the CRO and biopharma space, Dr. Santoro is a solid addition to our accomplished team. We look forward to his expert advice in all stages of development and his contributions to enhance our comprehensive medical affairs offerings for SynteractHCR clients,” said Steve Powell, CEO.
Santoro earned his medical degree from Ohio State University College of Medicine and his undergraduate degree from Miami University in Ohio.
SynteractHCR is a full-service international contract research organization (CRO) with a successful three-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies in six continents and more than 60 countries, offering broad therapeutic expertise, with notable depth in oncology, immunotherapy, CNS, and infectious disease, among other indications.